RemeGen Co. Ltd. Class A
688331
Kedudukan dalam Saham
#2475
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces,... RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.
Harga Saham
$14.13
Modal Pasaran
$7.91B
Perubahan (1 hari)
-2.50%
Perubahan (1 tahun)
3.41%
Negara
CN
Perdagangan RemeGen Co. Ltd. Class A (688331)
Kategori
Healthcare
EPS untuk RemeGen Co. Ltd. Class A (688331)
EPS setakat June 2026 TTM: $1.51
Menurut laporan kewangan terkini dan harga saham RemeGen Co. Ltd. Class A, EPS semasa syarikat (TTM) adalah $1.51. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $-0.40 peningkatan berbanding EPS tahun 2022 iaitu $-0.27.
Sejarah EPS untuk RemeGen Co. Ltd. Class A dari 2018 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $1.51 | -506.95% |
| 2024 | $-0.37 | -5.46% |
| 2023 | $-0.40 | 45.17% |
| 2022 | $-0.27 | -403.79% |
| 2021 | $0.09 | -134.26% |
| 2020 | $-0.26 | 102.63% |
| 2019 | $-0.13 | 58.72% |
| 2018 | $-0.08 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | 1,050.30% |
US
|
|
| $-7.98 | -629.99% |
US
|
|
| $-5.29 | -451.33% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | 1,742.33% |
NL
|
